Concepedia

Brendan M. Johnson

BM

Statistics

Publications

30

Citations

1.7K

H-Index

22

Active since

1992

Affiliations

GlaxoSmithKline (United States)(Current)

Research Triangle Park Foundation

GlaxoSmithKline (United Kingdom)

Monash University

Roivant Sciences (United States)

Brendan M. Johnson is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacotherapy, and pharmacology.

ORCID

Top concepts

Publications per year

1992–2023

30

Publications

30

An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine

Brendan M. Johnson, William N. Charman, Christopher J. H. Porter · AAPS PharmSci · 2002 · 190 citations · Full text

Four-Week Studies of Oral Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia

Louis Holdstock, Amy M. Meadowcroft, Rayma Maier et al. · Journal of the American Society of Nephrology · 2015 · 189 citations

, , +16

A Novel Hypoxia-Inducible Factor−Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial

Richard A. Brigandi, Brendan M. Johnson, Coreen Oei et al. · American Journal of Kidney Diseases · 2016 · 159 citations · Full text

CHARACTERIZATION OF TRANSPORT PROTEIN EXPRESSION IN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP) 2-DEFICIENT RATS

Brendan M. Johnson, Peijin Zhang, John D. Schuetz et al. · Drug Metabolism and Disposition · 2005 · 113 citations

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis

Amy M. Meadowcroft, Borut Čižman, Louis Holdstock et al. · Clinical Kidney Journal · 2018 · 103 citations · Full text

1–5 of 30